



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75406

**Title:** Elevation of Urotensin II level in patients with inflammatory bowel disease

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05665395

**Position:** Peer Reviewer

**Academic degree:** N/A

**Professional title:** Director, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-27 04:56

**Reviewer performed review:** 2022-01-28 02:33

**Review time:** 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

the Urotensin II (U-II) levels in inflammatory bowel disease (IBD) patients are significantly higher than that in healthy control subjects. To provide future guidance for the management of cardiovascular risks in IBD patients, additional studies with more clinical samples to compare U-II levels in IBD patients and control subjects are worth to be done. This will clarify the possible roles of inflammation factors and related signaling pathways (like EPK1/2, NF- $\kappa$ B and Rho/ROCK) in the pathophysiology of IBD. Perhaps this is a meaningful study, but further research is needed to confirm it, requiring a large sample and multi-center study.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75406

**Title:** Elevation of Urotensin II level in patients with inflammatory bowel disease

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05078269

**Position:** Editorial Board

**Academic degree:** MD, MSc, PhD

**Professional title:** Chief Doctor, Full Professor, Surgeon

**Reviewer's Country/Territory:** Brazil

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-02-03 12:59

**Reviewer performed review:** 2022-02-06 01:18

**Review time:** 2 Days and 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors should be congratulated for the comments sent as a letter to the editor. Some corrections involve shortening the second paragraph that does not contribute to the development of the reader's reasoning "IBD comprising of Crohn's disease (CD) and ulcerative colitis (UC) ....." . The withdrawal of the statement "these clinical data suggested interestingly that U-II could be involved in the pathophysiology of IBD, especially in the inflammatory responses and disease outcomes." would be welcome as it is not possible to state by the original design of the analyzed study. The counterpoints are pertinent and can enrich the authors' perspective on advancing in the field of research.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75406

**Title:** Elevation of Urotensin II level in patients with inflammatory bowel disease

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05665395

**Position:** Peer Reviewer

**Academic degree:** N/A

**Professional title:** Director, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-27

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2022-04-29 08:12

**Reviewer performed review:** 2022-04-29 08:49

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Some improvements have been made.